Evidence map›Paper›PMID 42221604›Full record

ArticleJournal of hepatocellular carcinoma2026

Multimodal Conversion Therapy Enabling Curative Resection in Giant Hepatocellular Carcinoma with Arteriovenous Fistula: A Case Report.

Hengcheng Zhong, Lanju Tan, Wenjun Le, Ning Luo, Yongqi Shen, Guangyu Long, Chun Xiong, Haiyun Tao

Abstract readCase Reports
In one paragraph

Article in Journal of hepatocellular carcinoma, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Hengcheng Zhong *Department of Tumor Hematology, The First Affiliated Hospital of Guangxi University of Science and Technology, Liuzhou, Guangxi, People's Republic of China.
Lanju Tan *First Clinical Medical College, Guangxi University of Science and Technology, Liuzhou, Guangxi, People's Republic of China.
Wenjun LeDepartment of Tumor Hematology, The First Affiliated Hospital of Guangxi University of Science and Technology, Liuzhou, Guangxi, People's Republic of China.
Ning LuoDepartment of General Surgery, Xiangzhou County Hospital of Traditional Chinese Medicine, Laibin, Guangxi, People's Republic of China.ORCID 0009-0009-0675-5918
Yongqi ShenDepartment of Tumor Hematology, The First Affiliated Hospital of Guangxi University of Science and Technology, Liuzhou, Guangxi, People's Republic of China.
Guangyu LongDepartment of Diagnostic Radiology, The First Affiliated Hospital of Guangxi University of Science and Technology, Liuzhou, Guangxi, People's Republic of China.
Chun XiongDepartment of Tumor Hematology, The First Affiliated Hospital of Guangxi University of Science and Technology, Liuzhou, Guangxi, People's Republic of China.
Haiyun TaoDepartment of Tumor Hematology, The First Affiliated Hospital of Guangxi University of Science and Technology, Liuzhou, Guangxi, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Giant hepatocellular carcinoma (GHCC) with arteriovenous fistula (AVF) is often considered a surgical no-go zone, lacking a standardized conversion therapy. This paper reports a case in which the implementation of sequential, integrated multimodal therapy, simultaneously targeting the tumor's biological behavior and the fistula's abnormal hemodynamics, successfully achieved substantial downstaging of the tumor, ultimately accomplishing curative resection. Case Presentation: A 38-year-old male patient presented with recurrent abdominal distension and was diagnosed GHCC complicated by AVF, as confirmed by computed tomography (CT). The patient underwent tumor downstaging through a multimodal therapeutic approach, which integrated targeted therapy, immunotherapy, hepatic artery infusion chemotherapy (HAIC), transcatheter arterial chemoembolization (TACE), and radiotherapy. This comprehensive treatment strategy subsequently facilitated curative surgical resection. To date, the patient has attained an overall survival duration of 32 months. Conclusion: This case suggests that a sequential multimodal strategy may enable downstaging and potential curative resection in selected patients; however, validation in larger cohorts is required.

Indexed as

Arteriovenous fistulaGiant Hepatocellular CarcinomaImmunotherapyRadiotherapy InterventionsTargeted Therapy

Identifiers

PMID42221604
PMCPMC13222008

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.